Fideuram Intesa Sanpaolo Private Banking S.P.A. Purchases New Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC

Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 134,689 shares of the company’s stock, valued at approximately $954,000.

Several other large investors have also added to or reduced their stakes in the business. Pinnacle Wealth Management Advisory Group LLC bought a new position in shares of Bicycle Therapeutics during the 4th quarter worth approximately $71,000. Woodstock Corp lifted its position in shares of Bicycle Therapeutics by 21.8% during the 4th quarter. Woodstock Corp now owns 29,146 shares of the company’s stock worth $206,000 after buying an additional 5,219 shares in the last quarter. Armistice Capital LLC lifted its position in shares of Bicycle Therapeutics by 6.4% during the 3rd quarter. Armistice Capital LLC now owns 2,978,000 shares of the company’s stock worth $23,050,000 after buying an additional 178,000 shares in the last quarter. Long Focus Capital Management LLC lifted its position in shares of Bicycle Therapeutics by 7.7% during the 3rd quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock worth $10,981,000 after buying an additional 101,402 shares in the last quarter. Finally, Moore Capital Management LP lifted its position in shares of Bicycle Therapeutics by 66.7% during the 3rd quarter. Moore Capital Management LP now owns 125,000 shares of the company’s stock worth $968,000 after buying an additional 50,000 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Kevin Lee sold 5,967 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $4.91, for a total value of $29,297.97. Following the completion of the transaction, the chief executive officer directly owned 613,029 shares in the company, valued at approximately $3,009,972.39. The trade was a 0.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 9,992 shares of company stock valued at $49,363. 22.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have commented on BCYC. Morgan Stanley dropped their target price on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 8th. Citizens Jmp dropped their target price on shares of Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Wednesday, March 18th. Truist Financial set a $8.00 target price on shares of Bicycle Therapeutics in a research report on Tuesday, March 17th. Oppenheimer dropped their target price on shares of Bicycle Therapeutics from $44.00 to $36.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 18th. Finally, Royal Bank Of Canada decreased their price target on shares of Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating for the company in a research note on Wednesday, March 18th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $14.00.

Bicycle Therapeutics Stock Up 2.2%

Shares of BCYC stock opened at $4.55 on Friday. The company has a 50 day moving average of $4.79 and a 200-day moving average of $5.86. Bicycle Therapeutics PLC Sponsored ADR has a 12-month low of $4.24 and a 12-month high of $9.36. The firm has a market cap of $317.18 million, a P/E ratio of -1.44 and a beta of 1.56.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.25). Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%.The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $7.50 million. As a group, equities analysts expect that Bicycle Therapeutics PLC Sponsored ADR will post -1.98 EPS for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.